No Data
No Data
No Data
Hong Kong stock market dynamics | Pharmaron (03759) rose more than 4% again as company demand gradually recovers and new order signings in the first half of the year show steady growth.
Pharmaron (03759) rose over 4% again. As of press time, it increased by 4.1% to HKD 9.65, with a turnover of HKD 42.8724 million.
Contract research organizations are generally increasing. Pharmaron (03759) rose 6.66%, and Orient Securities is expected to see marginal improvement in the sector.
Jingu Financial News| The concept of contract research organizations is rising across the board. As of the time of publication, Pharmaron (03759) rose 6.66%, Viva Biotech (01873) rose 5.05%, Tigermed (03347) rose 2.84%, and Wuxi Bio (02269) rose 2.77%. On the news side, Orient Securities stated that according to the latest data on the key indicators of the CRO industry's prosperity index, the global fund has basically stabilized, while the domestic investment and financing side is still tight; however, the enthusiasm for research and development has not diminished, and the IND and new clinical trials are still at a high level. The bank believes that the CXO sector, after experiencing double killings in performance and valuation, is expected to welcome a
Unusual event report | CRO concept stocks rose collectively, with the top companies signing new orders with double-digit growth in amount, and the sector is expected to see marginal improvement.
CRO concept stocks collectively rose. As of press time, Pharmaron (03759) rose 7.23% to HKD 9.34, Viva Biotech (01873) rose 3.03% to HKD 0.51, and Tigermed (03347) rose 2.84% to HKD 30.75.
HK stocks soar | Pharmaron (03759) rose more than 5%, Q2 revenue increased month-on-month, and the company expects a maximum of 45% year-on-year growth in net profit for the middle term.
Pharmaron (03759) rose over 5% and as of the time of publication, has increased by 4.48%, with a price of HKD 9.1 and a trading volume of 11.535 million HKD.
Pharmaron (03759) expects a year-on-year increase of up to 45% in its net profit for the first half of the year.
Kanglong Huacheng (03759) announced that the interim results as of June 30, 2024. Net income attributable to shareholders of the listed company was between RMB 1.055 billion and RMB 1.143 billion, an increase of about 34%-45% year-on-year. Revenue was between RMB 5.471 billion and RMB 5.64 billion, a decrease of 0%-3% year-on-year. Basic earnings per share were between RMB 0.5953 and RMB 0.6448 per share. The reasons for the performance changes are: 1) In the first quarter of 2024, the company's revenue decreased by 1.95% year-on-year. 2) In the second quarter of 2024.
Pharmaron expects its net income attributable to the parent company to increase by 34% to 45% year-on-year to 1.055 billion to 1.143 billion yuan in the first half of the year.
Pharmaron (03759) has announced that it expects the company's revenue for the period from January 1, 2024 to June 30, 2024 to be between 5.471 billion yuan and 5.64 billion yuan, representing a decrease of 0%-3% year-on-year; net income attributable to shareholders of the listed company is expected to increase by 34%-45% year-on-year to 1.055 billion yuan-1.143 billion yuan.
No Data